Akoya Biosciences Inc - Asset Resilience Ratio
Akoya Biosciences Inc (AKYA) has an Asset Resilience Ratio of 6.38% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Akoya Biosciences Inc debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Akoya Biosciences Inc's Asset Resilience Ratio has changed over time. See Akoya Biosciences Inc net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Akoya Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see AKYA company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $7.19 Million | 6.38% |
| Total Liquid Assets | $7.19 Million | 6.38% |
Asset Resilience Insights
- Limited Liquidity: Akoya Biosciences Inc maintains only 6.38% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Akoya Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Akoya Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087 |
Medical Instruments & Supplies | 9.08% |
|
Vizionfocus Inc.
TW:4771 |
Medical Instruments & Supplies | 5.07% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 4.42% |
|
Nanosonics Ltd
AU:NAN |
Medical Instruments & Supplies | 51.82% |
|
SDI Ltd
AU:SDI |
Medical Instruments & Supplies | 6.36% |
|
Austco Healthcare Ltd
AU:AHC |
Medical Instruments & Supplies | 15.90% |
|
Trajan Group Holdings Ltd
AU:TRJ |
Medical Instruments & Supplies | 0.23% |
|
Osteopore Ltd
AU:OSX |
Medical Instruments & Supplies | 43.09% |
Annual Asset Resilience Ratio for Akoya Biosciences Inc (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Akoya Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 18.61% | $23.26 Million | $125.00 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $180.37 Million | -- |
| 2022-12-31 | 3.97% | $6.99 Million | $176.03 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $190.91 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $77.66 Million | -- |
| 2019-12-31 | 11.21% | $10.02 Million | $89.41 Million | -- |
About Akoya Biosciences Inc
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions for transforming discovery, clinical research, and diagnostics in North America, the Asia-Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImag… Read more